SCHEMBL6464512

SCHEMBL6464512

CC(C)(c1cc(Cl)c(-n2ncc(=O)[nH]c2=O)c(Cl)c1)c1nc(-c2ccccc2Cl)c(-c2cccc(C(N)=O)c2)s1

nearest known ligand 0.34

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
P2RX7 Q99572 4/20 0.34
ABCB11 O95342 1/20 0.34
BTK Q06187 3/20 0.33
MAP2K4 P45985 2/20 0.33
TTK P33981 1/20 0.33
CHEK2 O96017 1/20 0.33
KDM4E B2RXH2 1/20 0.33
TP53 P04637 1/20 0.33
GAA P10253 1/20 0.33
HPGD P15428 1/20 0.33
NPSR1 Q6W5P4 1/20 0.33
HSD17B10 Q99714 1/20 0.33
PSD A5PKW4 1/20 0.33
SCN9A Q15858 2/20 0.32
ADORA2A P29274 1/20 0.32
ADORA1 P30542 1/20 0.32
KDR P35968 1/20 0.31
MAPK14 Q16539 2/20 0.31
MAPK8 P45983 1/20 0.31
MAPK10 P53779 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7135587 0.81 P2RX7 (0.38) P2RX7ABCB11
SCHEMBL6461628 0.78 ADORA2A (0.38) P2RX7ABCB11BTKKDM4EADORA2A
SCHEMBL6461284 0.74 P2RX7 (0.35) P2RX7ABCB11CNR1CNR2
SCHEMBL7705284 0.73 P2RX7 (0.34) P2RX7ABCB11BTKMAP2K4MAPK14
SCHEMBL6459898 0.70 THRB (0.39) P2RX7ABCB11
SCHEMBL6461977 0.70 THRB (0.36) P2RX7ABCB11
SCHEMBL6454694 0.68 P2RX7 (0.40) P2RX7ABCB11KDM4ETP53GAA
SCHEMBL6455203 0.66 THRB (0.44) P2RX7ABCB11
SCHEMBL6454146 0.66 THRB (0.36) P2RX7ABCB11KDM4EGAA
SCHEMBL6462050 0.65 P2RX7 (0.41) P2RX7ABCB11KDM4ENPSR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6894046-B2 IL-5 inhibiting 6-azauracil derivatives JANSSEN PHARMACEUTICA N.V. (BE) 2005-05-17 US disclosed
EP-1114046-B1 INTERLEUKIN-5 INHIBITING 6-AZAURACIL DERIVATIVES JANSSEN PHARMACEUTICA NV (BE) 2003-04-23 EP disclosed
US-20020010177-A1 IL-5 inhibiting 6-azauracil derivatives JANSSEN CILAG S.A. (FR) 2002-01-24 US disclosed
EP-1114046-A1 INTERLEUKIN-5 INHIBITING 6-AZAURACIL DERIVATIVES Janssen Pharmaceutica N.V. (BE) 2001-07-11 EP disclosed
WO-2000017195-A1 INTERLEUKIN-5 INHIBITING 6-AZAURACIL DERIVATIVES JANSSEN PHARMACEUTICA N.V. (BE) 2000-03-30 WO disclosed
EP-0987265-A1 Interleukin-5 inhibiting 6-azauracil derivatives JANSSEN PHARMACEUTICA N.V. (BE) 2000-03-22 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020010177-A1 IL-5 inhibiting 6-azauracil derivatives ALOX5, IL5, IL6ST P2RX7 880/4885ABCB11 2670/4885BTK 4039/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.